via xconomy.com
So Big Pharma—which has been consolidating through mega-mergers into what amounts to an oligopoly—has sized up a situation it can exploit, Kinsella says. It has been offering up stingy terms to biotech companies that provide practically zero return to the people who shouldered all the risk from the biotech company’s early days. This kind of hardball negotiating has potential to push the whole biotech industry to the brink of extinction, Kinsella argues. After a while, it becomes like commercial overfishing, he says.
No comments:
Post a Comment